A Phase 1, Dose Escalation Study of Flotetuzumab, a CD123 x CD3 DART Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia.

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date9/07/19 → 31/12/24
View all
View less

Keywords

  • Malignant Haematology
  • Acute Myeloid Leukemia
  • Clinical trial